Beam Therapeutics (BEAM) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
17 Nov, 2026Platform and pipeline
Base editing targets single-letter mutations; delivery approaches include ex vivo transplant and in vivo LNP/mRNA infusion, with alpha-1 antitrypsin, GSD1a and PKU programs using in vivo delivery.
PKU dosing is planned for early 2027; three editors are expected to address up to 50% of the disease, while 8–10 editors could address ~80%.
FDA platform rules may allow multiple editors and guide RNAs within one IND, trial and BLA; adding further editors could rely on in vitro potency and safety data if covered by clinical validation.
Sickle cell disease
Positive BEACON top-line results keep the program on track for a BLA filing as early as December 2026; further data are expected at ASH.
Reported hematology profile includes higher fetal hemoglobin, lower sickle hemoglobin and a 60/40 ratio; faster neutrophil and platelet engraftment may reduce transplant toxicity and hospital time.
To date, no investigator-reported VOEs; the goal is a rate at least competitive with the 89%–90% range cited for CASGEVY and LYFGENIA, with further reporting expected.
BEACON median time from first mobilization to dosing was 4.5 months, and two-thirds of patients needed one mobilization; internal manufacturing, quality release and automation support faster processing.
The category comprising CASGEVY and LYFGENIA was forecast to exceed $700 million in sales this year; the target population for these therapies was characterized as ~10% of patients, or 10,000 people.
Alpha-1 antitrypsin
The pivotal 50-patient trial began dosing in July 2026; enrollment is expected to finish in H1 2027, followed by one year of follow-up, with data discussed as potentially available in H1 2028.
Editing has raised average AAT levels from a disease range of 4–6 µM to the mid-teens, with over 90% normal M protein; levels can rise further during illness, reaching the mid-20s as described.
FDA alignment supports a potential U.S. accelerated approval submission based on the pivotal study; a 2029 market launch was described as a reasonable scenario following H1 2028 data and a later filing.
The intended population is patients with lung pathology, with or without liver disease; one infusion aims to reduce toxic Z protein and restore protective M protein, addressing both organs.
U.S. prevalence was estimated at at least 100,000, with 10,000–15,000 diagnosed and treated and at least 8,000–9,000 on augmentation therapy; the global trial network spans 15 sites in six countries.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update